摘要
目的探究泛昔洛韦联合胸腺肽对生殖器疱疹患者的T淋巴细胞亚群及slL-2R水平的具体影响。方法选取2017年11月至2018年5月青海省人民医院诊治的124例生殖器疱疹患者作为研究对象。采用随机分组法,分成两组。62例患者仅予以泛昔洛韦治疗,为对照组;另外62例患者予以泛昔洛韦与胸腺肽联合治疗生殖器疱疹,为观察组。比较两组的临床疗效、T淋巴细胞亚群改变、slL-2R水平改变、复发频次及不良反应。结果治疗后,观察组的自觉症状消失时间、止疱时间、结痂时间、皮损愈合时间及痊愈时间均明显短于对照组(P<0.05);观察组的CD3+、CD4+、CD4+/CD8+均明显高于对照组;观察组的CD8+明显低于对照组(P<0.05);观察组的slL-2R水平显著低于对照组(P<0.05);观察组的复发频次显著少于对照组(P<0.05)。观察组的不良反应发生率(3.23%)明显低于对照组(12.90%,P<0.05)。结论对生殖器疱疹患者予以泛昔洛韦、胸腺肽联合治疗,可显著改善患者的T淋巴细胞亚群、slL-2R水平,帮助患者快速消失临床症状,减少复发频次,临床应用安全性较高,值得生殖器疱疹临床治疗中大力推广。
Objective To investigate the specific effects of famciclovir combined with thymosin on T lymphocyte subsets and slL-2 R levels in patients with genital herpes. Methods A total of 124 patients with genital herpes admitted to our hospital from November 2017 to May 2018 were randomly divided into two groups. 62 patients were treated with famciclovir alone, and the other 62 patients were treated with famciclovir and thymosin. The clinical efficacy, T lymphocyte subsets, slL-2 R levels and recurrence rates were compared between the two groups. Results After treatment, the disappearance time of subjective symptoms, blistering time, scarring time, skin healing time and healing time of the observation group were significantly shorter than those of the control group(P<0.05). The CD3+, CD4+, CD4+/CD8+ levels were significantly higher and the CD8+ level was significantly lower in the observation group than those in the control group, with statistically significant differences(P<0.05). The level of slL-2 R in the observation group was significantly lower than that of the control group(P<0.05);the frequency of recurrence in the observation group was significantly less than that of the control group(P<0.05). The incidence of adverse reaction in the observation group(3.23%) was significantly lower than that of the control group(12.90%)(P<0.05). Conclusions The combined treatment of famciclovir and thymosin can significantly improve the level of T lymphocyte subsets and slL-2 R in patients with genital herpes, accelerate the disappearance of clinical symptoms and reduce recurrence rate. With high clinical safety, it is worthy of vigorous promotion in clinical.
作者
赵洁
刘雪山
刘霞
马嘉敏
ZHAO Jie;LIU Xueshan;LIU Xia;MA Jiamin(Department of Dermatology,Qinghai People's Hospital,Xining 810000,Qinghai,China)
出处
《中国性科学》
2019年第12期132-136,共5页
Chinese Journal of Human Sexuality
